Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

1 year ago

TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of…

Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

1 year ago

WILMETTE, Ill., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing…

Sofwave Obtains U.S. Patent for Fat Tissue Reduction Technology

1 year ago

SAN CLEMENTE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in…

Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

1 year ago

Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a…

Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis

1 year ago

Rapid epinephrine absorption with a time to reach the 100 pg/mL threshold concentration in 9 minutes after dosingSustained pharmacokinetics (PK)…

Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

1 year ago

ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology…

Dark Horse Consulting Launches Initiative for Certification of Manufacturing Capabilities

1 year ago

ICMC: Initiative for Certification of Manufacturing Capabilities ICMC: Initiative for Certification of Manufacturing Capabilities, delivered by Dark Horse Consulting Group…

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

1 year ago

NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia’s…

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

1 year ago

Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million…